Table 5 Chemotherapy regimens received by patients in the non-cisplatin group
Type of chemotherapy | Number of patients (%) N = 200 |
|---|---|
Capecitabine + Oxaliplatin/5-FU + Leucovorin + Oxaliplatin/Epirubicin + Oxaliplatin + Capecitabine | 34 (17) |
5-FU + Irinotecan + Leucovorin/5-FU + Irinotecan + Leucovorin + Cetuximab/Irinotecan + Cetuximab | 18 (9) |
Doxorubicin + Cyclophophamide/5-FU + Epirubicin + Cyclophophamide/Epirubicin + Cyclophophamide | 24 (12) |
Paclitaxel/Paclitaxel + Herceptin | 22 (11) |
Docetaxel/Docetaxel + Herceptin | 26 (13) |
Adrimacycin + Ifosfamide | 8 (4) |
Carboplatin + Paclitaxel | 34 (17) |
CHOP/ABVD (Cyclophosphamide + Adriamycin + Vincristine + Prednisone)/(Adriamycin + Bleomycin + Vinblastine + Dacarbazine) | 12 (6) |
VAC alternating with IE (Vincristine + Adriamycin + Cyclophosphamide alternating with Ifosfamide + Etoposide) | 4 (2) |
5-FU + Oxaliplatin + Irinotecan + Leucovorin | 8 (4) |
Gemcitabine | 6 (3) |
Carboplatin + Gemcitabine | 2 (1) |
Others | 2 (1) |